Markets:

Overview

News

Currencies

International

Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

23.67 -0.03 (-0.13%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

December 07, 2022

From Vor Biopharma

Via GlobeNewswire

First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

December 07, 2022

From Vor Biopharma

Via GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

November 22, 2022

From Vor Biopharma

Via GlobeNewswire

Expert Ratings for Vor Biopharma ↗

May 13, 2022

Analysts have provided the following ratings for Vor Biopharma (NASDAQ:VOR) within the last quarter:

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 25, 2022

On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

November 10, 2022

From Vor Biopharma

Via GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

November 01, 2022

From Vor Biopharma

Via GlobeNewswire

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

October 12, 2022

From Vor Biopharma

Via GlobeNewswire

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

October 11, 2022

From Vor Biopharma

Via GlobeNewswire

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

September 28, 2022

Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates

From Vor Biopharma

Via GlobeNewswire

Why Virios Therapeutics Is Trading Lower By 75%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗

September 20, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million.

Via Benzinga

3 Biotech Stock Picks From This Wedbush Analyst ↗

July 27, 2022

While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2022 ↗

July 26, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 06, 2022

Gainers

Via Benzinga

76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More ↗

June 23, 2022

Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 22, 2022

Via Benzinga

79 Biggest Movers From Yesterday ↗

June 08, 2022

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 16, 2022

On Monday, 198 companies reached new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 13, 2022

On Friday, 153 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 07, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) stock rose 45.8% to $2.77 during Thursday's regular session. Trevi Therapeutics's stock is trading at a volume of 15.2...

Via Benzinga

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

March 22, 2022

From Akron BioProducts

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

March 28, 2022

On Monday, 147 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 ↗

December 17, 2021

Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 3, 2021 ↗

December 03, 2021

Upgrades Cowen & Co. upgraded the previous rating for Marvell Technology Inc (NASDAQ:

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 02, 2021

Gainers Biofrontera (NASDAQ:BFRI) shares ...

Via Benzinga

61 Biggest Movers From Yesterday ↗

December 03, 2021

Gainers Jowell Global Ltd. (NASDAQ: JWEL) jumped 25.5% to close at $13.36. Jowell Global recently announced a collaboration with Unilever's Uni-Excubator. Information...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2021 ↗

December 02, 2021

Upgrades According to William Blair, the prior rating for Graco Inc (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.